The Food and Drug Administration (FDA) has said “no” to a new drug called rintatolimod (Ampligen) made by Hemispherx Inc. for the treatment of chronic fatigue syndrome (CFS). The FDA wants to see more data and a new clinical trial before it approves its use.
In December, the Members of the Arthritis Advisory Committee voted against the use of the drug 9-5 due to inadequate data provided by Hemispherx. The FDA usually follows such recommendations, though no legal obligation exists for it follow them.
Powered by Facebook Comments